bluuebunny/crossref_metadata_2025_split huggingface dataset:
ChemInform Abstract: Ruthenium Catalyzed Hydroaminoalkylation of Isoprene via Transfer Hydrogenation: Byproduct‐Free Prenylation of Hydantoins.
Authors: Schmitt Daniel C. , Lee Jungyong , Dechert‐Schmitt Anne‐Marie R. , Yamaguchi Eiji , Krische Michael J. 
Published: October 2013

AbstractIsoprene is added to arylated hydantoins in the absence of a directing group.
ChemInform Abstract: Microwave Assisted Synthesis of 3,5‐Disubstituted 1,2,4‐Oxadiazoles from Substituted Amidoximes and Benzoyl Cyanides.
Authors: Kandre Shivaji , Bhagat Pundlik Rambhau , Sharma Rajiv , Gupte Amol 
Published: October 2013

AbstractThe simple protocol renders possible the synthesis of oxadiazoles including the complex structure (V) via O‐carboxyphenyl amidoxime intermediates.
ChemInform Abstract: Ln[N(SiMe3)2]3‐Catalyzed Cycloaddition of Terminal Alkynes to Azides Leading to 1,5‐Disubstituted 1,2,3‐Triazoles: New Mechanistic Features.
Authors: Hong Longcheng , Lin Weijia , Zhang Fangjun , Liu Ruiting , Zhou Xigeng 
Published: October 2013

AbstractThe first example of rare earth metal‐catalyzed cycloaddition of terminal alkynes (I) to azides (II) resulting in the formation of 1,5‐disubstituted 1,2,3‐triazoles (III) is described.
ChemInform Abstract: Microwave‐Assisted Synthesis of 3‐Methyl‐1‐phenylchromeno[4,3‐c]pyrazol‐4(1H)‐ones under Solvent‐Free Conditions.
Authors: Yang Guo‐Yu , Yang Jing‐Tian , Wang Cai‐Xia , Fan Su‐Fang , Xie Pu‐Hui , Xu Cui‐Lian 
Published: October 2013

AbstractCompared with existing methods, this novel green and atom economical methodology for the synthesis of chromenopyrazolones (II) and (IV) affords the target products in higher yields and shorter reaction times.
ChemInform Abstract: Synthesis of Highly Substituted Isocoumarins by Rhodium‐Catalyzed Annulation of Readily Available Benzoic Acids.
Authors: Unoh Yuto , Hirano Koji , Satoh Tetsuya , Miura Masahiro 
Published: October 2013

AbstractRhodium‐catalyzed oxidative coupling of benzoic acid (I) with alkynes provides isocoumarin derivatives.
ChemInform Abstract: Pd‐Catalyzed Oxidative C—H/C—H Cross‐Coupling of Pyridines with Heteroarenes.
Authors: Liu Bo , Huang Yumin , Lan Jingbo , Song Feijie , You Jingsong 
Published: October 2013

AbstractThe authors present a highly selective C2‐heteroarylation of pyridines and related azines.
ChemInform Abstract: Tandem Synthesis of Pyrroloacridones via [3 + 2] Alkyne Annulation/Ring‐Opening with Concomitant Intramolecular Aldol Condensation.
Authors: Verma Akhilesh K. , Kotla Siva K. Reddy , Aggarwal Trapti , Kumar Sonu , Nimesh Hemlata , Tiwari Rakesh K. 
Published: October 2013

AbstractAn efficient cascade reaction is developed for the synthesis of functionalized biologically important pyrroloacridones starting from easily accessible iodo‐pyranoquinolines.
ChemInform Abstract: Novel and Chemoselective Dehydrogenation of 3,4‐Dihydropyrimidin‐2(1H)‐ones with 1,4‐Bis(triphenylphosphonium)‐2‐butene Peroxodisulfate.
Authors: Gorjizadeh Maryam 
Published: October 2013

AbstractThe present method tolerates a wide variety of functionalities, including oxidizable groups, cf.
ChemInform Abstract: Novel Synthetic Methodologies. Part 226. Synthesis of Dihydrobenzo[1,4]oxazines Using Copper‐Catalyzed Intramolecular Ring Closure Reaction.
Authors: Jangili Paramesh , Kashanna Jajula , Das Biswanath 
Published: October 2013

AbstractThe starting adducts are prepared by treatment of cyclic sulfamidates with 2‐halophenols following a known procedure.
ChemInform Abstract: Chiral β‐Iodoamines by Urea‐Catalyzed Iodocyclization of Trichloroacetimidates.
Authors: Brindle Cheyenne S. , Yeung Charles S. , Jacobsen Eric N. 
Published: October 2013

AbstractThe resulting products are converted to a variety of polyfunctional amine‐containing chiral building blocks.
ChemInform Abstract: In Search of 3d/4f‐Metal Single‐Molecule Magnets. Nickel(II)/Lanthanide(III) Coordination Clusters
Authors: Polyzou Christina D. , Efthymiou Constantinos G. , Escuer Albert , Cunha‐Silva Luis , Papatriantafyllopoulou Constantina , Perlepes Spyros P. 
Published: October 2013

AbstractReview: 76 refs.
ChemInform Abstract: Hall Mobility in Tin Iodide Perovskite CH3NH3SnI3: Evidence for a Doped Semiconductor.
Authors: Takahashi Yukari , Hasegawa Hiroyuki , Takahashi Yukihiro , Inabe Tamotsu 
Published: October 2013

AbstractCrystals of the title compound are prepared by transferring EtOH into a flask containing stoichiometric quantities of SnI2 and MeNH3I (65 °C followed by cooling to 5 °C, 10—30% yield).
ChemInform Abstract: Magnetic Properties of the RbMnPO4 Zeolite‐ABW‐Type Material: A Frustrated Zigzag Spin Chain.
Authors: Nenert Gwilherm , Bettis Jerry Jr. , Kremer Reinhard , Yahia Hamdi Ben , Ritter Clemens , Gaudin Etienne , Isnard Olivier , Whangbo Myung‐Hwan 
Published: October 2013

AbstractRbMnPO4 zeolite powder is prepared by solid state reaction of a stoichiometric mixture of Rb2CO3, MnO, and (NH4)H2PO4 (1.
ChemInform Abstract: Thermal Properties and Phase Transitions in (NH4)3ZrF7
Authors: Fokina V. D. , Gorev M. V. , Bogdanov E. V. , Pogoreltsev E. I. , Flerov I. N. , Laptash N. M. 
Published: October 2013

Abstractheat capacity, thermal dilatation, permittivity, and T‐p phase diagram
ChemInform Abstract: KSi2P3: A New Layered Phosphidopolysilicate (IV).
Authors: Feng Kai , Kang Lei , Yin Wenlong , Hao Wenyu , Lin Zheshuai , Yao Jiyong , Wu Yicheng 
Published: October 2013

AbstractThe new title compound is synthesized by solid state reaction from mixtures of KP, Si, and P in the molar ratio of 1:2:2 (750 °C, 4 d).
ChemInform Abstract: Synthesis and Structure of Perovskite ScMnO3.
Authors: Chen Haiyan , Yu Tian , Gao Peng , Bai Jianming , Tao Jing , Tyson Trevor A. , Wang Liping , Lalancette Roger 
Published: October 2013

AbstractPolycrystalline hexagonal ScMnO3 is prepared by solid state reaction of a stoichiometric mixture of Sc2O3 and MnO2 (calcination in air at 1000 °C, 10 h, intermittent sintering and annealing at 1100 °C, 10 h in O2).
ChemInform Abstract: Room Temperature and Solvent‐Free Iridium‐Catalyzed Selective Alkylation of Anilines with Alcohols.
Authors: Li Jia‐Qi , Andersson Pher G. 
Published: October 2013

AbstractA novel bidentate iridium NHC‐phosphine complex is developed, which appears to be an efficient catalyst for the N‐alkylation of anilines with alcohols.
ChemInform Abstract: First Asymmetric Synthesis of Planar Chiral [2.2]Metacyclophanes.
Authors: Blangetti Marco , Mueller‐Bunz Helge , O'Shea Donal F. 
Published: October 2013

AbstractThe final enantioselective step is achieved using a (‐)‐sparteine mediated aryl lithiation, followed by treatment with various electrophiles.
ChemInform Abstract: A Cooperative Hydrogen‐Bond‐Promoted Organophotoredox Catalysis Strategy for Highly Diastereoselective, Reductive Enone Cyclization.
Authors: Neumann Matthias , Zeitler Kirsten 
Published: October 2013

AbstractThis new method gives trans‐1,2‐cycloalkanes and heterocycles providing the first example of combining photoredox approach with hydrogen‐bond catalysis.
ChemInform Abstract: (IPr)Pd(pydc) (pydc = Pyridine‐2,6‐dicarboxylate) — A Highly Active Precatalyst for the Sterically Hindered C—N Coupling Reactions.
Authors: Li Yan‐Jing , Zhang Jin‐Ling , Li Xiao‐Jian , Geng Yu , Xu Xiao‐Hua , Jin Zhong 
Published: October 2013

AbstractNovel N‐heterocyclic carbene complexes incorporating a pyridine‐2‐carboxylate or pyridine‐2,6‐dicarboxylate ligand are synthesized and successfully applied as catalysts in the Buchwald—Hartwig amination reaction of sterically hindered aryl chlorides.
ChemInform Abstract: The Synthesis of α,α‐Difluoroacetamides via Electrophilic Fluorination in the Mixed‐Solvent of Water and PEG‐400.
Authors: Zhang Zhiguo , Bi Jingjing , Liu Qingfeng , Zhang Guisheng 
Published: October 2013

AbstractIn water/PEG‐400 the reactions proceed in nearly quantitative conversions within hours without the need of any additional phase transfer catalyst.
ChemInform Abstract: Application of Tartarate Derived Bidentate Bioxazolines in Enantioselective Addition of Terminal Alkynes to Imines.
Authors: Balaraman Kaluvu , Vasanthan Ravichandran , Kesavan Venkitasamy 
Published: October 2013

AbstractA new class of bidentate bisoxazoline ligands is applied to the addition of alkynes to imines.
ChemInform Abstract: Trace Amount Cu (ppm)‐Catalyzed Intramolecular Cyclization of 2‐(gem‐Dibromovinyl)phenols(thiophenols) to 2‐Bromobenzofurans(thiophenes).
Authors: Ji Yong , Li Pinhua , Zhang Xiuli , Wang Lei 
Published: October 2013

AbstractThe required catalytic traces of copper species are already contained in commercially available cesium carbonate (Shanghai, 99.9%, Cu 47 ppm).
ChemInform Abstract: Organocatalytic Asymmetric Desymmetrization: Efficient Construction of Spirocyclic Oxindoles Bearing a Unique All‐Carbon Quaternary Stereogenic Center via Sulfa‐Michael Addition.
Authors: Yao Lu , Liu Kang , Tao Hai‐Yan , Qui Guo‐Fu , Zhou Xiang , Wang Chun‐Jiang 
Published: October 2013

AbstractThe bifunctional amine‐thiourea catalyst effects excellent stereoselectivities.
ChemInform Abstract: A Simple and Expeditious Synthesis of 2,3,6‐Trisubstituted Tetrahydropyrans Through (3,5)‐Oxonium‐ene Cyclization Using Molecular Iodine.
Authors: Raju N. Prudhvi , Reddy B. Jagan Mohan , Anjibabu R. , Muralikrishna K. , Reddy B. V. Subba 
Published: October 2013

AbstractA simple and selective method allows the synthesis of tetrahydropyrane derivatives via iodine‐mediated coupling of aldehydes with hept‐5‐en‐2‐ols.
ChemInform Abstract: Catalytic Asymmetric Conjugate Addition of Grignard Reagents to Chromones.
Authors: Vila Carlos , Hornillos Valentin , Fananas‐Mastral Martin , Feringa Ben L. 
Published: October 2013

AbstractThe reaction takes advantage of the reduced reactivity of the resulting magnesium enolates, tolerating a broad scope of alkyl Grignards including secondary alkyl magnesium reagents.
ChemInform Abstract: Synthesis of a New Class of Tetronic Acid Derivatives: A One‐Pot Three‐Component Condensation Reaction Between Isoquinoline or Pyridine and Dialkyl Acetylenedicarboxylate with Tetronic Acid.
Authors: Rezayan Ali Hossein , Sabahi Hossein , Rahmati Abbas , Maleki Ali , Kheirjou Somayyeh 
Published: October 2013

AbstractTetronic acid derivatives [(IV) and (VI)] are smoothly synthesized via 1:1:1 addition reaction.
ChemInform Abstract: Novel Quinolone Substituted Thiazolidin‐4‐ones as Antiinflammatory, Anticancer Agents: Design, Synthesis and Biological Screening.
Authors: Suthar Sharad Kumar , Jaiswal Varun , Lohan Sandeep , Bansal Sumit , Chaudhary Anil , Tiwari Amit , Alex Angel Treasa , Joesph Alex 
Published: October 2013

AbstractThe title compounds are tested for their anti‐inflammatory and anticancer activity.
ChemInform Abstract: Tetrahydroquinolines by Lewis Acid‐Promoted Friedel—Crafts Cyclizations.
Authors: Bunce Richard A. , Cain Nicholas R. , Cooper John G. 
Published: October 2013

AbstractUse of FeCl3 as Lewis acid promoter proves to be superior for unsubstituted and alkyl‐substituted substrates, whereas more reactive AlCl3 is necessary for substrates possessing heteroatom functionality.
ChemInform Abstract: Thermal Induced Intramolecular [2 + 2] Cycloaddition of Allene‐ACPs.
Authors: Chen Kai , Sun Run , Xu Qin , Wei Yin , Shi Min 
Published: October 2013

AbstractA facile protocol for preparation of bicyclo[4.2.0] heterocycles containing a nitrogen atom is developed starting from allene‐alkylidenecyclopropanes.
ChemInform Abstract: Synthesis and Anticancer Activity of Novel 2‐Pyridyl Hexahydrocyclooctathieno[2,3‐d]pyrimidine Derivatives.
Authors: Kassab Asmaa E. , Gedawy Ehab M. 
Published: October 2013

AbstractThe synthesis of the titled compounds along with their anticancer activities against various cancer‐cell lines is described.
ChemInform Abstract: Unveiling Latent α‐Iminocarbene Reactivity for Intermolecular Cascade Reactions Through Alkyne Oxidative Amination.
Authors: Mace Nina , Thornton Aaron R. , Blakey Simon B. 
Published: October 2013

AbstractThe present protocol provides a metallonitrene/alkyne cascade which is terminated by ylide formation and [2,3] Wittig rearrangement.
Synthesis and Preliminary Evaluation of 1‐[18F]Fluoro‐1‐deoxy‐2,5‐anhydro‐D‐mannitol as a PET Radiotracer for Breast Cancer Imaging
Authors: Niu Ben , Wen Xiaoan , Jia Zhijun , Wu Xiaoming , Guo Wanhua , Sun Hongbin 
Published: October 2013

Abstract1‐[18F]Fluoro‐1‐deoxy‐2,5‐anhydro‐D‐mannitol (3, 18F‐FDAM) has been synthesized in 6 steps starting from 2,5‐anhydro‐D‐mannitol (2,5‐AM) and evaluated as a new radiotracer for PET imaging of MCF‐7 breast tumor. The result of PET imaging study showed that 3 displayed a slightly higher uptake by breast tumor in comparison with the normal breast tissue, implying the possibility of development of PET radiotracers based on targeting fructose transporters.
Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma
Authors: Mailhot Vega Raymond B. , Kim Jane , Bussière Marc , Hattangadi Jona , Hollander Abby , Michalski Jeff , Tarbell Nancy J. , Yock Torunn , MacDonald Shannon M. 
Published: October 2013

BACKGROUNDProton therapy has been a hotly contested issue in both scientific publications and lay media. Proponents cite the modality's ability to spare healthy tissue, but critics claim the benefit gained from its use does not validate its cost compared with photon therapy. The objective of this study was to evaluate the cost effectiveness of proton therapy versus photon therapy in the management of pediatric medulloblastoma.METHODSA cost‐effective analysis was performed from the societal perspective using a Monte Carlo simulation model. A population of pediatric medulloblastoma survivors aged 18 years was studied who had received treatment at age 5 years and who were at risk of developing 10 adverse events, such as growth hormone deficiency, coronary artery disease, ototoxicity, secondary malignant neoplasm, and death. Costing data included the cost of investment and the costs of diagnosis and management of adverse health states from institutional and Medicare data. Longitudinal outcomes data and recent modeling studies informed risk parameters for the model. Incremental cost‐effectiveness ratios were used to measure outcomes.RESULTSResults from the base case demonstrated that proton therapy was associated with higher quality‐adjusted life years and lower costs; therefore, it dominated photon therapy. In 1‐way sensitivity analyses, proton therapy remained the more attractive strategy, either dominating photon therapy or having a very low cost per quality‐adjust life year gained. Probabilistic sensitivity analysis illustrated the domination of proton therapy over photon therapy in 96.4% of simulations.CONCLUSIONSBy using current risk estimates and data on required capital investments, the current study indicated that proton therapy is a cost‐effective strategy for the management of pediatric patients with medulloblastoma compared with standard of care photon therapy. Cancer 2013;119:4299–4307. © 2013 American Cancer Society.
Treatment trade‐offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies
Authors: Burnette Brian L. , Dispenzieri Angela , Kumar Shaji , Harris Ann M. , Sloan Jeff A. , Tilburt Jon C. , Kyle Robert A. , Rajkumar S. Vincent 
Published: October 2013

BACKGROUNDTwo randomized trials have demonstrated improved progression‐free survival (PFS) with lenalidomide maintenance after autologous transplantation for multiple myeloma (MM). Overall survival (OS) results are conflicting, and quality‐of‐life (QOL) data are lacking. The authors conducted a systematic survey of patients with MM regarding what constitutes a meaningful benefit that would make burdens of maintenance treatments (toxicity and cost) acceptable.METHODSA self‐administered survey was mailed to 1159 consecutive, living patients who were evaluated at Mayo Clinic. The survey provided background information on the standard of care for MM and data on maintenance. Patients were asked to estimate the magnitude of OS benefit that would be acceptable for various degrees of toxicity and cost.RESULTSOf 1159 surveys sent, 886 patients (83.2%) responded, and 736 patients returned a completed survey (66% raw response rate). The most worrisome potential toxicity was identified as peripheral neuropathy by 27% of patients, cytopenias by 24%, deep vein thrombosis by 20%, fatigue by 15%, nausea by 8%, and diarrhea/constipation by 7%. If treatment was free, had no toxicity, and the OS benefit was ≤1 year, then 49% of patients indicated that they would choose maintenance; with moderate toxicity, this proportion decreased to 42%. Adding a treatment cost of $25 per month decreased the proportion that would choose maintenance to 39% of patients.CONCLUSIONSThe current results indicated that willingness to receive maintenance treatment declined when actual benefits were provided in concrete numeric terms compared with a general statement of PFS benefit. The authors also observed that the magnitude of benefit required to consider maintenance was affected by cost and toxicity. Cancer 2013;119:4308–4315. © 2013 American Cancer Society.
Bevacizumab (BVZ)‐associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT‐11)
Authors: Fangusaro Jason , Gururangan Sridharan , Poussaint Tina Young , McLendon Roger E. , Onar‐Thomas Arzu , Warren Katherine E. , Wu Shengjie , Packer Roger J. , Banerjee Anu , Gilbertson Richard J. , Jakacki Regina , Gajjar Amar , Goldman Stewart , Pollack Ian F. , Friedman Henry S. , Boyett James M. , Kun Larry E. , Fouladi Maryam 
Published: October 2013

BACKGROUNDThe incidence and spectrum of acute toxicities related to the use of bevacizumab (BVZ)‐containing regimens in children are largely unknown. This report describes the adverse events in a recently completed large phase 2 trial of BVZ plus irinotecan (CPT‐11) in children with recurrent central nervous system tumors.METHODSPediatric Brain Tumor Consortium trial‐022 evaluated the efficacy and toxicity of BVZ (10 mg/kg administered intravenously) as a single agent for 2 doses given 2 weeks apart and then combined with CPT‐11 every 2 weeks (1 course = 4 weeks) in children with recurrent central nervous system tumors. Children were treated until they experienced progressive disease, unacceptable toxicity or completed up to a maximum of 2 years of therapy. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. Patients who received at least 1 dose of BVZ were included for toxicity assessment.RESULTSBetween October 2006 and June 2010, 92 patients evaluable for toxicity were enrolled and received 687 treatment courses. The most common toxicities attributable to BVZ included grade I‐III hypertension (38% of patients), grade I‐III fatigue (30%), grade I‐II epistaxis (24%), and grade I‐IV proteinuria (22%). Twenty‐two patients (24%) stopped therapy due to toxicity.CONCLUSIONSThe combination of BVZ and CPT‐11 was fairly well‐tolerated, and most severe BVZ‐related toxicities were rare, self‐limiting, and manageable. Cancer 2013;119:4180–4187. ©2013 American Cancer Society.
Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer
Authors: Zylla Dylan , Gourley Brett L. , Vang Derek , Jackson Scott , Boatman Sonja , Lindgren Bruce , Kuskowski Michael A. , Le Chap , Gupta Kalpna , Gupta Pankaj 
Published: October 2013

BACKGROUNDPreclinical studies show that opioids stimulate angiogenesis and tumor progression through the mu opioid receptor (MOR). Although MOR is overexpressed in several human malignancies, the effect of chronic opioid requirement on cancer progression or survival has not been examined in humans.METHODSWe performed a retrospective analysis on 113 patients identified in the Minneapolis VA Tumor Registry (test cohort) and 480 patients from the national VA Central Cancer Registry (validation cohort) who had been diagnosed with stage IV prostate cancer between 1995 and 2010 to examine whether MOR expression or opioid requirement is associated with disease progression and survival. All opioids were converted to oral morphine equivalents for comparison. Laser scanning confocal microscopy was used to analyze MOR immunoreactivity in prostate cancer biopsies. The effects of variables on outcomes were analyzed in univariable and multivariable models.RESULTSIn patients with metastatic prostate cancer, MOR expression and opioid requirement were independently associated with inferior progression‐free survival (hazard ratio [HR] 1.65, 95% confidence interval [CI] 1.33‐2.07, P<.001 and HR 1.08, 95% CI 1.03‐1.13, P<.001, respectively) and overall survival (HR 1.55, 95% CI 1.20‐1.99, P<.001 and HR 1.05, 95% CI 1.00‐1.10, P = .031, respectively). The validation cohort confirmed that increasing opioid requirement was associated with worse overall survival (HR 1.005, 95% CI 1.002‐1.008, P = .001).CONCLUSIONHigher MOR expression and greater opioid requirement are associated with shorter progression‐free survival and overall survival in patients with metastatic prostate cancer. Nevertheless, clinical practice should not be changed until prospective randomized trials show that opioid use is associated with inferior clinical outcomes, and that abrogation of the peripheral activities of opioids ameliorates this effect. Cancer 2013;119:4103–4110. ©2013 American Cancer Society.
In vitro dissolution and in vivo bioequivalence evaluation of two brands of trimetazidine tablets
Authors: Helmy Sally A. , Mansour Noha O. 
Published: October 2013

AbstractTrimetazidine is an effective anti‐anginal agent and anti‐ischaemic effect. The objective of this study was to assess the in vitro dissolution and to evaluate the bioavailability of two brands of trimetazidine dihydrochloride tablets. Prior to the in vivo PKs study, an in vitro comparative dissolution test was performed for 2 oral brands of trimetazidine dihydrochloride tablets (20 mg). In vivo PKs study was evaluated in 24 healthy male volunteers after a single dose oral administration in an open, randomized, two‐way crossover study with a washout period of 1 week. After an overnight fast, human volunteers were randomly allocated to receive a single dose of either test or reference product. Blood samples were collected over a 24‐hour period following drug administration and plasma was analyzed for trimetazidine concentrations using a validated high‐performance liquid chromatography assay method. The PK parameters Cmax, AUC0−t, AUC0−∞, tmax, and t1/2 were determined from plasma concentration‐time profiles. The 90% confidence intervals for the ratio of log transformed values of Cmax, AUC0−t, and AUCt−∞ of the test product over those of reference were within the acceptable range (0.8–1.25) for bioequivalence. As a result, the 2 trimetazidine formulations are considered bioequivalent and thus could be prescribed interchangeably in the medical practice based on its PK effect and biopharmaceutical performance.